Status:
COMPLETED
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
Lead Sponsor:
Emory University
Conditions:
Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
This pilot clinical trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in treating patients with castration resistant prostate cancer that ...
Detailed Description
PRIMARY OBJECTIVE: Establish the feasibility of using gallium Ga 68-DOTATATE (68Ga-DOTATATE) PET as a predictive imaging biomarker for neuroendocrine transdifferentiation in prostate cancer. SECONDA...
Eligibility Criteria
Inclusion
- Patients with metastatic castration resistant prostate carcinoma with skeletal, visceral and/or nodal involvement
- Ability to lie still for PET scanning
- Patients must be able to provide written informed consent
Exclusion
- Patients less than 18 years of age
- Patients without metastatic castration resistant prostate carcinoma with skeletal, visceral and/or nodal involvement
- Inability to lie still for PET scanning
- Patients unable to provide written informed consent
Key Trial Info
Start Date :
February 22 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 6 2023
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT03448458
Start Date
February 22 2018
End Date
February 6 2023
Last Update
July 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States, 30322